Epizyme Inc (NASDAQ:EPZM) Institutional Investors Quarterly Sentiment

June 16, 2018 - By Adrian Mccoy

Epizyme, Inc. (NASDAQ:EPZM) Logo

Sentiment for Epizyme Inc (NASDAQ:EPZM)

Epizyme Inc (NASDAQ:EPZM) institutional sentiment increased to 1.5 in 2018 Q1. Its up 0.29, from 1.21 in 2017Q4. The ratio is positive, as 57 active investment managers increased and opened new holdings, while 38 sold and reduced equity positions in Epizyme Inc. The active investment managers in our partner’s database now have: 57.44 million shares, up from 56.93 million shares in 2017Q4. Also, the number of active investment managers holding Epizyme Inc in their top 10 holdings decreased from 3 to 2 for a decrease of 1. Sold All: 13 Reduced: 25 Increased: 35 New Position: 22.

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the United States. The company has market cap of $1.04 billion. The Company’s product candidates include tazemetostat, an inhibitor of the EZH2 HMT, which is in five-arm Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma ; Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II and Ib clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial for elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function, as well as Phase II clinical trial in adult patients with ovarian cancer. It currently has negative earnings. The firm is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL.

The stock decreased 5.68% or $0.9 during the last trading session, reaching $14.95. About 891,290 shares traded or 105.12% up from the average. Epizyme, Inc. (NASDAQ:EPZM) has risen 14.24% since June 16, 2017 and is uptrending. It has outperformed by 1.67% the S&P500.

Analysts await Epizyme, Inc. (NASDAQ:EPZM) to report earnings on August, 3. They expect $-0.53 earnings per share, down 10.42 % or $0.05 from last year’s $-0.48 per share. After $-0.49 actual earnings per share reported by Epizyme, Inc. for the previous quarter, Wall Street now forecasts 8.16 % negative EPS growth.

Foresite Capital Management Ii Llc holds 9.2% of its portfolio in Epizyme, Inc. for 1.56 million shares. Nea Management Company Llc owns 6.46 million shares or 5.1% of their US portfolio. Moreover, Oracle Investment Management Inc has 1.7% invested in the company for 396,325 shares. The California-based Redmile Group Llc has invested 1.38% in the stock. Rock Springs Capital Management Lp, a Maryland-based fund reported 1.28 million shares.

Since January 1, 0001, it had 0 insider purchases, and 1 insider sale for $1.20 million activity.

Epizyme, Inc. (NASDAQ:EPZM) Ratings Coverage

Ratings analysis reveals 100% of Epizyme’s analysts are positive. Out of 7 Wall Street analysts rating Epizyme, 7 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $20 while the high is $25.0. The stock’s average target of $22.57 is 50.97% above today’s ($14.95) share price. EPZM was included in 9 notes of analysts from January 10, 2018. H.C. Wainwright maintained it with “Buy” rating and $25.0 target in Wednesday, March 14 report. The firm has “Buy” rating by SunTrust given on Monday, April 23. The rating was initiated by Roth Capital on Thursday, February 1 with “Buy”. The firm has “Buy” rating given on Tuesday, April 24 by Roth Capital. The stock of Epizyme, Inc. (NASDAQ:EPZM) earned “Buy” rating by Leerink Swann on Tuesday, April 24. Leerink Swann maintained Epizyme, Inc. (NASDAQ:EPZM) rating on Wednesday, March 14. Leerink Swann has “Outperform” rating and $24 target. The firm has “Outperform” rating by Wedbush given on Tuesday, April 24. The stock of Epizyme, Inc. (NASDAQ:EPZM) earned “Buy” rating by Jefferies on Wednesday, January 24.

More notable recent Epizyme, Inc. (NASDAQ:EPZM) news were published by: Seekingalpha.com which released: “Epizyme’s tazemetostat shows positive effect in mid-stage lymphoma study” on June 15, 2018, also Nasdaq.com with their article: “Report: Developing Opportunities within Silicon Motion Technology, Green Brick Partners, Alliance Resource Partners …” published on June 06, 2018, Nasdaq.com published: “Epizyme to Host Investor Conference Call to Discuss Interim Follicular Lymphoma Clinical Data” on June 01, 2018. More interesting news about Epizyme, Inc. (NASDAQ:EPZM) were released by: Streetinsider.com and their article: “Epizyme (EPZM) Phase 2 Data of Tazemetostat for Malignant Mesothelioma Met Primary Endpoint” published on June 04, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid …” with publication date: June 15, 2018.

Epizyme, Inc. (NASDAQ:EPZM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: